胰腺癌相关糖尿病与2型糖尿病在糖稳态多方面存在差异
研究纳入28例未治疗胰腺导管腺癌相关糖尿病(PDAC-DM)和97例2型糖尿病患者,病程均在3年内,行混合餐耐量试验。PDAC-DM胰岛素敏感性约为2型糖尿病的2.5倍,胰岛素分泌低约81%,β细胞功能低约40%,胰岛素清除更高,餐后胰高血糖素和GLP-1更高。两组代谢差异在调整年龄、性别和BMI后持续存在。
要点
- PDAC-DM以胰岛素缺乏为主,胰岛素敏感性高于2型糖尿病。
- PDAC-DM胰岛素清除率更高,餐后胰高血糖素和GLP-1水平更高。
- 两组代谢差异独立于年龄、性别和BMI,提示可指导个体化治疗。
核心结论
- PDAC-DM与2型糖尿病在代谢层面可区分,高血糖缺陷机制不同。
研究设计与样本
- 横断面研究纳入癌症初治PDAC-DM患者28例和2型糖尿病患者97例,糖尿病病程均在3年内,行混合餐耐量试验。
主要发现
- PDAC-DM胰岛素敏感性较2型糖尿病高约2.5倍。
- PDAC-DM胰岛素分泌较2型糖尿病低约81%,β细胞功能低约40%。
- PDAC-DM胰岛素清除率高于2型糖尿病,无论是否校正胰岛素敏感性。
- 两组餐后胰高血糖素和GLP-1均升高,但PDAC-DM组更高;GIP水平组间相似。
- 代谢差异在调整年龄、性别和BMI后持续存在。
临床怎么用
- PDAC-DM以胰岛素缺乏为主且胰岛素敏感性较高,提示高血糖治疗需个体化。
- 代谢特征差异可能为早期PDAC诊断的生物标志物发现提供线索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Pancreatic ductal adenocarcinoma-related diabetes mellitus (PDAC-DM) is a paraneoplastic syndrome with a poorly understood pathophysiology. PDAC-DM is often clinically confused with type 2 diabetes, resulting in delayed cancer detection and poorly individualised hyperglycaemia treatment. We investigated whether these forms of diabetes can be distinguished at the metabolic level. METHODS: Adults with either cancer treatment-naive PDAC-DM (n=28) or type 2 diabetes (n=97), and with diabetes onset within 3 years, underwent mixed-meal tolerance tests to investigate glucose metabolism. Outcomes included insulin sensitivity (Matsuda index), insulin secretion (insulinogenic index), beta cell function (oral disposition index), insulin clearance, and postprandial glucagon, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) responses. RESULTS: Compared with type 2 diabetes, individuals with PDAC-DM showed ~2.5-fold greater insulin sensitivity, ~81% lower insulin secretion and ~40% lower beta cell function. Insulin clearance was higher in the PDAC-DM group than the type 2 diabetes group, with and without adjustment for insulin sensitivity. Glucagon and GLP-1 levels increased after a meal in both groups, but levels were higher in the PDAC-DM group. GIP levels were similar between groups. The metabolic differences between groups persisted after adjustment for age, sex and BMI. CONCLUSIONS/INTERPRETATION: PDAC-DM and type 2 diabetes are metabolically distinct, with different defects responsible for hyperglycaemia. PDAC-DM is characterised predominantly by insulin deficiency and displays higher insulin sensitivity than type 2 diabetes. There are also differences in alpha cell regulation and insulin clearance compared with type 2 diabetes. These findings identify biological characteristics that may have implications for individualised treatment of PDAC-DM and guide diagnostic biomarker discovery for early PDAC diagnosis.
引用
- Toledo FGS, Li Y, Wang F, et al. Pancreatic cancer-related diabetes and type 2 diabetes differ in multiple aspects of glucose homeostasis. Diabetologia. 2025. PMID: 40991017. doi:10.1007/s00125-025-06543-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。